Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna said Tuesday its Covid-19 vaccine was more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose.

Moderna says new data shows its Covid vaccine is more than 90% effective against virus six months after second shot

Moderna's COVID-19 vaccine remains highly protective six months after a person receives their second shot, according to updated data the biotech released Tuesday.  Just over 90% of trial participants who had received their full immunizations half a year ago had not been diagnosed with COVID-19, Moderna reported. The vaccine was even more effective against severe cases of the viral disease, protecting 95% of the trial participants.

New data shows Moderna's vaccine remains highly protective 6 months after shots

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna provides clinical and supply updates on COVID-19 Vaccine program ahead of 2nd annual Vaccines Day.

Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day

Peloton

Zoom Video

Tesla

Tesla Inc (NASDAQ: TSLA) shares are trading higher on continued strength following Monday's Canaccord Genuity upgrade from Hold to Buy and price target update from $419 to $1,071. Another notable upgrade came last week from Daniel Ives of Wedbush, who upgraded Tesla to Outperform from Neutral and upped the price target from $950 to $1,000.

Here's Why Tesla, Moderna, Peloton And Zoom Are Moving

BioNTech SE

Shares of Moderna Inc. shot up 8.6% in morning trading, BioNTech SE ran up 5.7% toward a 4-month high and Pfizer Inc. climbed 1.1% toward a 3-month high, after U.S. health regulators paused the use of Johnson & Johnson's COVID-19 vaccine "out of an abundance of caution" as a result of rare blood clotting cases. Meanwhile, J&J shares shed $2.98, or 1.8%, to shave about 20 points of the Dow Jones Industrial Average's price, as the Dow dropped 132 points, or 0.4%.

Moderna, BioNTech stocks surge after regulators halt use of J&J vaccine

Novavax

Pfizer

Johnson & Johnson's (NYSE: JNJ) pain has proved to be gain for other vaccine companies, including BioNTech SE (NASDAQ: BNTX), Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX). What Happened: The Food and Drug Administration and the Centers for Disease Control and Prevention announced it's recommending pausing of the use of J&J's single-shot coronavirus vaccine, attributing the decision on incidents of severe, atypical blood clots.

Why Vaccine Stocks Pfizer, BioNTech, Moderna And Novavax Are Higher

Investors viewed bad news for Johnson and Johnson's COVID-19 vaccine as good news for Moderna and Pfizer on Tuesday, which both climbed after the CDC called for a pause in the use of J&J's single-dose COVID-19 vaccine. Shares of Moderna surged as much as 7%, while Pfizer and its COVID vaccine partner BioNTech jumped 1% and 3% in Tuesday trades, respectively. Shares of J&J dropped as much as 3% before paring a portion of those losses.

Moderna and Pfizer shares climb after CDC calls for pause in use of J&J COVID-19 vaccine

These 6 Words From Moderna's CMO May Mean Billions in 2022

The Moderna COVID-19 vaccine will start to be used in England from Tuesday, providing an alternative to the AstraZeneca vaccine for people aged under 30.

Moderna COVID-19 vaccine rollout begins in England, giving under 30s alternative to AstraZeneca

It can already claim it contributed to both companies' COVID vaccines.

A Surprising Vaccine Rival May Upset the Dreams of Anyone Holding Moderna and Pfizer Stock

Will Worse Side Effects for Moderna's Vaccine Boost Pfizer's Fortunes?

England is now offering jabs to people aged over 45 after the UK hit its vaccination target. All adults over 50, the clinically vulnerable and health and social care workers have now been offered a coronavirus (COVID-19) vaccine in the country.

Coronavirus: England offers jabs to over-45s after hitting vaccination target, begins Moderna Inc rollout

AstraZeneca

Johnson & Johnson

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

Castor Maritime Inc

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 6.6% after French health officials on Thursday said an mRNA vaccine can be used in place of the second shot from AstraZeneca.  Additionally, White House COVID-19 Response Coordinator Jeff Zients recently said the U.S. is on track of meeting the goal of 100 million shots in 100 days.

What's Going On With Moderna Stock And Castor Maritime Stock Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at the 20th Annual Needham Virtual Healthcare Conference.

Moderna to Present at the 20th Annual Needham Virtual Healthcare Conference

AbbVie

ACADIA Pharma

Alexion Pharma

Biogen

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

Like Moderna's vaccine revenue so far? The future's even brighter.

This Is Why Moderna Is a Great Stock to Buy Right Now

Covid-19 vaccine stocks have had a solid run, driven by the urgency to end the pandemic and the unprecedented speed at which companies have developed highly effective vaccines. Our theme of Covid-19 Vaccine Stocks - which includes Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), Johnson & Johnson.

Moderna, Novavax: Are Covid Vaccine Stocks Still Worth Investing In?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna highlights publication of antibody persistence data of its COVID-19 Vaccine out to 6 months in The New England Journal of Medicine.

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine

Baidu

These big-name stocks are trading at significant discounts from highs reached earlier in the year.

Is It Time to Buy the Nasdaq's Biggest Dippers?

Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Moderna (MRNA): Will It Gain?

The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX). Several allergic reaction incidents, including serious episodes known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

NIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 Vaccines

Moderna performed well throughout 2020 which was a major transition year for the company, with Q2 of positive FCF. 2021 will be a massive year for the company with more than $18 billion of revenue and Q4 of positive FCF.

Post The COVID-19 Run-Up, Moderna Looks Interesting

The NIH said it has begun looking at why some people have suffered from allergic reactions after receiving the Pfizer-BioNTech and Moderna Covid-19 vaccines.

U.S. begins study assessing allergic reactions to Pfizer and Moderna Covid vaccines

MRNA is on record that it will not enforce COVID-19 vaccine patents amid the pandemic. President Biden is contemplating suspending IP rights for COVID-19 vaccines. The idea appears to have mainstream appeal.

News for Moderna Stock (MRNA)